There are 859 resources available
Novel checkpoint combinations for advanced NSCLC
Presenter: Byoung Chul Cho
Session: GSK - Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors: Expert perspectives
Resources:
Webcast
General Q&A and closing
Presenter: All Speakers
Session: GSK - Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors: Expert perspectives
Resources:
Webcast
Setting the scene: Overview of key inequalities in the Asia-Pacific (AP) region and worldwide
Presenter: Ravindran Kanesvaran
Session: ‘Levelling up’: Reducing inequalities in outcomes through the use of global standards
Resources:
Slides
Anticancer treatment at the end of life: When to stop, when to proceed
Presenter: Gudrun Kreye
Session: Supporting shared decision making in face of uncertainty
Resources:
Slides
Webcast
129O - Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Presenter: Do-Youn Oh
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
258MO - Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study
Presenter: Marniza Saad
Session: Mini oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
Inequities in access to standards of care in the AP region
Presenter: Minit Shah
Session: ‘Levelling up’: Reducing inequalities in outcomes through the use of global standards
Resources:
Slides
Webcast
Supporting caregivers of patients with advanced cancer
Presenter: Stein Kaasa
Session: Supporting shared decision making in face of uncertainty
Resources:
Slides
Webcast
130O - The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Presenter: Sun Young Rha
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
260MO - Impact of starting treatment choice in metastatic castration-sensitive prostate cancer (mCSPC)
Presenter: masaki Shiota
Session: Mini oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast